Epithelial ovarian cancer: evolution of management in the era of precision medicine
S Lheureux, M Braunstein… - CA: a cancer journal for …, 2019 - Wiley Online Library
Ovarian cancer is the second most common cause of gynecologic cancer death in women
around the world. The outcomes are complicated, because the disease is often diagnosed …
around the world. The outcomes are complicated, because the disease is often diagnosed …
Onconephrology: the intersections between the kidney and cancer
MH Rosner, KD Jhaveri, BA McMahon… - CA: a cancer journal …, 2021 - Wiley Online Library
Onconephrology is a new subspecialty of nephrology that recognizes the important
intersections of kidney disease with cancer. This intersection takes many forms and includes …
intersections of kidney disease with cancer. This intersection takes many forms and includes …
Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis
RE Bristow, RS Tomacruz, DK Armstrong… - Journal of clinical …, 2002 - ascopubs.org
PURPOSE: To evaluate the relative effect of percent maximal cytoreductive surgery and
other prognostic variables on survival among cohorts of patients with advanced-stage …
other prognostic variables on survival among cohorts of patients with advanced-stage …
Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology …
RF Ozols, BN Bundy, BE Greer, JM Fowler… - Journal of Clinical …, 2003 - ascopubs.org
Purpose: In randomized trials the combination of cisplatin and paclitaxel was superior to
cisplatin and cyclophosphamide in advanced-stage epithelial ovarian cancer. Although in …
cisplatin and cyclophosphamide in advanced-stage epithelial ovarian cancer. Although in …
Nanocarriers for delivery of platinum anticancer drugs
Platinum based anticancer drugs have revolutionized cancer chemotherapy, and continue to
be in widespread clinical use especially for management of tumors of the ovary, testes, and …
be in widespread clinical use especially for management of tumors of the ovary, testes, and …
Clinical development of platinum complexes in cancer therapy: an historical perspective and an update
D Lebwohl, R Canetta - European journal of cancer, 1998 - Elsevier
The vast amount of basic research on platinum coordination complexes has produced, over
the past 25 years, several thousand new molecules for preclinical screening and 28 …
the past 25 years, several thousand new molecules for preclinical screening and 28 …
Toxicity of platinum compounds
JT Hartmann, HP Lipp - Expert opinion on pharmacotherapy, 2003 - Taylor & Francis
Since the introduction of platinum-based combination chemotherapy, particularly cisplatin,
the outcome of the treatment of many solid tumours has changed. The leading platinum …
the outcome of the treatment of many solid tumours has changed. The leading platinum …
Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study
SM Eisenkop, RL Friedman, HJ Wang - Gynecologic oncology, 1998 - Elsevier
Objective. Despite correlation between the completeness of surgical cytoreduction and
survival for patients with advanced ovarian cancer, relatively few undergo complete …
survival for patients with advanced ovarian cancer, relatively few undergo complete …
Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function
PE Kintzel, RT Dorr - Cancer treatment reviews, 1995 - Elsevier
The narrow therapeutic index of anticancer drugs presents a clinical dilemma when these
agents are administered to patients with impaired or unstable renal function. The purpose of …
agents are administered to patients with impaired or unstable renal function. The purpose of …
[HTML][HTML] Review of therapeutic drug monitoring of anticancer drugs part 1–cytotoxics
Most anticancer drugs are characterised by a steep dose–response relationship and narrow
therapeutic window. Inter-individual pharmacokinetic (PK) variability is often substantial. The …
therapeutic window. Inter-individual pharmacokinetic (PK) variability is often substantial. The …